IL58673A - Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same - Google Patents

Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same

Info

Publication number
IL58673A
IL58673A IL58673A IL5867379A IL58673A IL 58673 A IL58673 A IL 58673A IL 58673 A IL58673 A IL 58673A IL 5867379 A IL5867379 A IL 5867379A IL 58673 A IL58673 A IL 58673A
Authority
IL
Israel
Prior art keywords
isolation
membrane proteins
neisseria meningitidis
containing same
vaccines containing
Prior art date
Application number
IL58673A
Other versions
IL58673A0 (en
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of IL58673A0 publication Critical patent/IL58673A0/en
Publication of IL58673A publication Critical patent/IL58673A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Process for the isolation of membrane proteins from Neisseria meningitidis which comprises treating the organism with the aqueous solution of a detergent in a concentration of 0.1 to 2% w/v for 15 minutes to 24 hours, allowing the mixture to stand, optionally with agitation, separating the extract from the bacterial residue and optionally carrying out a further purification.
IL58673A 1978-11-11 1979-11-09 Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same IL58673A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782848965 DE2848965A1 (en) 1978-11-11 1978-11-11 METHOD FOR PRODUCING MEMBRANE PROTEINS FROM NEISSERIA MENINGITIDIS AND VACCINE CONTAINING THEM

Publications (2)

Publication Number Publication Date
IL58673A0 IL58673A0 (en) 1980-02-29
IL58673A true IL58673A (en) 1983-02-23

Family

ID=6054405

Family Applications (1)

Application Number Title Priority Date Filing Date
IL58673A IL58673A (en) 1978-11-11 1979-11-09 Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same

Country Status (9)

Country Link
EP (1) EP0011243B1 (en)
JP (1) JPS5566519A (en)
AT (1) ATE857T1 (en)
AU (1) AU533386B2 (en)
CA (1) CA1142083A (en)
DE (2) DE2848965A1 (en)
DK (1) DK154841C (en)
ES (1) ES485715A1 (en)
IL (1) IL58673A (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317811A (en) 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
CA1221626A (en) * 1982-12-02 1987-05-12 Milan Blake Iga binding protein
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
ES2278446T3 (en) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. B / C COMBINED VACCINES AGAINST MENINGITIS.
BR0010721A (en) 1999-05-19 2002-06-11 Chiron Spa Compositions of combined neisseries
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
DE20321889U1 (en) * 2002-08-02 2012-03-12 Glaxosmithkline Biologicals S.A. vaccine composition
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CU23313A1 (en) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia MÃ0 / 00 METHOD OF OBTAINING COCLEAR STRUCTURES VACCINAL COMPOSITIONS AND ADJUSTS BASED ON COCLEAR STRUCTURES AND THEIR INTERMEDIARIES
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
JP5173194B2 (en) * 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP2032161B1 (en) 2006-06-12 2012-07-11 GlaxoSmithKline Biologicals S.A. L3v los vaccines
BRPI0818545A2 (en) 2007-10-19 2017-07-04 Novartis Ag meningococcal vaccine formulations
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
CN102596240B (en) 2009-08-27 2015-02-04 诺华股份有限公司 Hybrid polypeptides including meningococcal fHBP sequences
WO2011024071A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
TWI445708B (en) 2009-09-02 2014-07-21 Irm Llc Compounds and compositions as regulators of TLR activity
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
AU2010339921B2 (en) 2009-12-15 2016-08-11 Glaxosmithkline Biologicals S.A. Homogeneous suspension of immunopotentiating compounds and uses thereof
JP2013521326A (en) 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic composition
AU2011288203A1 (en) 2010-03-18 2012-08-23 Novartis Ag Adjuvanted vaccines for serogroup B meningococcus
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
ES2759484T3 (en) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococcus that overexpresses NadA and / or NHBA and external membrane vesicles derived from it
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
BR112014019166A2 (en) 2012-02-02 2017-07-04 Novartis Ag promoters for increased protein expression in meningococci
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
WO2013186753A1 (en) 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
BR112015005056A2 (en) 2012-09-06 2017-11-21 Novartis Ag combination vaccines with meningococcus serogroup b and d / t / p
EP4056198A3 (en) 2012-09-18 2022-12-07 GlaxoSmithKline Biologicals SA Outer membrane vesicles
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
MX2020002659A (en) 2017-09-08 2020-09-09 Evelo Biosciences Inc Bacterial extracellular vesicles.
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
SG11202103389WA (en) 2018-11-06 2021-05-28 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB202115072D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Also Published As

Publication number Publication date
AU533386B2 (en) 1983-11-24
DK154841C (en) 1989-06-05
AU5268279A (en) 1980-05-15
IL58673A0 (en) 1980-02-29
DE2962526D1 (en) 1982-05-27
ATE857T1 (en) 1982-04-15
EP0011243A1 (en) 1980-05-28
JPS5566519A (en) 1980-05-20
DE2848965A1 (en) 1980-05-22
DK154841B (en) 1988-12-27
JPS6350332B2 (en) 1988-10-07
EP0011243B1 (en) 1982-04-14
DK475779A (en) 1980-05-12
ES485715A1 (en) 1980-05-16
CA1142083A (en) 1983-03-01

Similar Documents

Publication Publication Date Title
DE2962526D1 (en) Process for preparing membrane proteins from neisseria meningitidis and vaccines containing them
DE69423383D1 (en) Production and uses of LOS-reduced outer membrane proteins from gram-negative cocci
ATE195420T1 (en) METHOD FOR PRODUCING EICOSAPENTORIC ACIDS
DE69224124D1 (en) Process for the preparation of dihomo-gamma-linolenic acid and the lipid contained therein
DE69116305D1 (en) Process for the production of trehalulose and isomaltulose
ZA838072B (en) Beta-carbolines,process for their production and pharmaceutical preparations containing them
ATE109823T1 (en) MALOLACTIC FERMENTATION OF WINE.
JPS6452726A (en) Method for removing endotoxin of pertussis, pertussis toxoid and production thereof
HUT44422A (en) Method and apparatus for improving the quality of roasted coffee
EP0090660A3 (en) Neisseria gonorrhoeae vaccine
AT384032B (en) METHOD FOR PRODUCING POLYDISPERSE NATIVE PSEUDOMONAS-FLAGELLA (H) -ANTIGENS (FAG)
YU45458B (en) Process for obtaining liquid ethanole extract of propolis
EP0607593A3 (en) Process for obtaining cell cultures with a higher content of autologous cytonines.
DE3574269D1 (en) Apparatus for the separation of products from a product-substrate mixture
DE3265664D1 (en) Process for the production of a biochemical vaccine against salmonella fevers
MA21382A1 (en) PROCESS FOR THE PREPARATION OF A JASMINE EXTRACT AND EXTRACT OBTAINED.
DE3366707D1 (en) Preparation of glucose dehydrogenase
EP0281978A3 (en) Inactivation of human immunodeficiency virus (hiv) in proteinic solutions by means of phenol
SU1515606A1 (en) Method of purification and isolation of sodium nitroprusside
GR3003137T3 (en) Process for the preparation of polychlorophosphazene
PT96134A (en) Process for obtaining mutants of oncostatin M
GB2018755A (en) Benzylidene esters
JPS6410950A (en) Elimination of taste and odor of substance rich in amino acid
UA14449A1 (en) Process for preparation of pantocrine
Lillich et al. Analysis of the intracellular amino acid pool and proteins from whole cells of Rhizobium japonicum

Legal Events

Date Code Title Description
HP Change in proprietorship
KB Patent renewed